Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

Scientists discover new genetic variants linked to bowel cancer

Cancer Research UK-funded scientists have discovered four new genetic variants linked to bowel cancer by combining data from three major genome studies, reveals a study published in Nature Genetics.

16 Nov 2010

Pro-Pharmaceuticals third quarter net loss decreases to $1,899,000

Pro-Pharmaceuticals, Inc., a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today reported its financial results for the third quarter and the nine months ended September 30, 2010. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the SEC.

12 Nov 2010

Screening colonoscopy rates for women do not increase when offered to be done by female endoscopists: Study

A new study from researchers in Colorado shows that women offered a female endoscopist were not more likely to undergo a screening colonoscopy than those who were not offered this choice. Past surveys have shown preferences for female endoscopists seem to be common among women. In this study, a patient outreach program failed to support the notion that rates of screening colonoscopy can be increased by offering women the option of a screening colonoscopy performed by a female endoscopist.

12 Nov 2010

SU2C to receive second CLIO Healthcare Award

The CLIO Healthcare Awards will present its second annual honorary award, to Stand Up To Cancer (SU2C), on November 12th, 2010. This dedicated award celebrates an organization or individual for excellence in healthcare communications and for contributing to the improvement of public health.

12 Nov 2010

Alnylam Pharmaceuticals presents ALN-VSP Phase I data for liver cancer at Chemotherapy Foundation Symposium

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today presented additional interim data from its ongoing Phase I trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement. The data were presented at the Chemotherapy Foundation Symposium being held in New York City.

11 Nov 2010

Exact Sciences completes underwritten public offering

Exact Sciences Corp. today announced that it has completed its previously announced underwritten public offering of common stock at a price of $6.00 per share.

10 Nov 2010

Data from AVEO's tivozanib-FOLFOX6 combination Phase 1b trial presented at 22nd EORTC-NCI-AACR

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that new clinical data from a Phase 1b trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with FOLFOX6, a standard chemotherapy regimen, will be presented during the 22nd Annual Symposium of EORTC-NCI-AACR being held November 16-19, 2010 in Berlin, Germany.

10 Nov 2010

Neogenix awarded $488,958.50 grant under QTDP program

Neogenix Oncology, Inc. announced today that the company has been awarded two grants totaling $488,958.50, under the Qualifying Therapeutic Discovery Project Program. The two successful applications were for the company's h16C3 therapeutic antibody development program and the diagnostic biomarker development program for both their h16C3 and NPC-1C antibodies.

10 Nov 2010

Study demonstrates potent anticancer properties of quinoxalinyl-piperazine compounds

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced the publication of a research article in Bioorganic & Medicinal Chemistry [18:7966-7974, 2010] on the anticancer activity of quinoxalinyl-piperazine compounds.

9 Nov 2010

Genetic region linked to survival in patients with advanced bowel cancer

Scientists have discovered a genetic region linked to survival in patients with advanced bowel cancer, according to a study being presented at the National Cancer Research Institute (NCRI) Cancer Conference today (Tuesday).

9 Nov 2010

Statins do not reduce risk for colorectal cancer in postmenopausal women

The use of statins among a group of postmenopausal women did not reduce the risk for colorectal cancer, according to the results of a prospective analysis of data from the large population-based Women's Health Initiative (WHI).

9 Nov 2010

Study finds anti-gout medication may reduce risk of colorectal cancer

Allopurinol, a relatively inexpensive anti-gout medication that has been on the market for more than 20 years, may have some activity against colorectal adenomas, according to data presented at the Ninth Annual AACR Frontiers in Cancer Prevention Research Conference, held here Nov. 7-10, 2010.

8 Nov 2010

Laparoscopic surgery safe and effective for removing bowel tumours

Laparoscopic or 'keyhole' surgery is a safe, effective way of removing bowel tumours and should be offered to all patients undergoing surgery for colorectal cancer, according to researchers from the University of Leeds.

8 Nov 2010

New findings could help scientists devise optimal therapies for Friedreich's ataxia

Scripps Research Institute scientists have taken a step closer to understanding the cause of Friedreich's ataxia, a debilitating neurological condition that affects tens of thousands of people worldwide, and so far has no cure.

8 Nov 2010

Plexxikon's PLX4032 shows positive data in patients with metastatic melanoma

Plexxikon today announced positive preliminary data from a pivotal Phase 2 clinical trial of PLX4032 (RG7204) in metastatic melanoma, showing significant tumor shrinkage in the majority of patients.

8 Nov 2010

Exact Sciences awarded $244,500 federal grant to develop Cologuard sDNA screening test

Exact Sciences Corp. today announced it has been awarded a $244,500 therapeutic discovery grant from the Internal Revenue Service to aid the company in its development of CologuardTM, an sDNA screening test aimed at detecting both colorectal cancers and pre-cancers.

3 Nov 2010

Immunomedics product candidates, technologies receive recognition from QTDP program

Immunomedics, Inc. a biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that all 12 applications from the Company were certified by the Internal Revenue Service of the Department of Treasury as qualified investments in accordance with the Qualifying Therapeutic Discovery Project (QTDP) program under section 48D of the Internal Revenue Code. As a result, the Company will receive an aggregate cash award of $2.9 million.

3 Nov 2010

Mouse study indicates black raspberries can prevent colorectal cancer

Black raspberries are highly effective in preventing colorectal tumors in two mouse models of the disease, according to a University of Illinois at Chicago study. The findings are published in the November issue of Cancer Prevention Research.

3 Nov 2010

Pro-Pharmaceuticals awarded $489,000 in federal grants under Qualifying Therapeutic Discovery Project

Pro-Pharmaceuticals, Inc., a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced it has been notified that it has been awarded approximately $489,000 total in two federal grants under the Qualifying Therapeutic Discovery Project ("QTDP") Program.

2 Nov 2010

NSAIDs drugs prevent colon cancer: Research

Nonsteroidal anti-inflammatory drugs (NSAIDs) prevent colon cancer by triggering diseased stem cells to self-destruct, according to researchers at the University of Pittsburgh Cancer Institute (UPCI) and the University of Pittsburgh School of Medicine.

2 Nov 2010

Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

Scientists discover new genetic variants linked to bowel cancer

Pro-Pharmaceuticals third quarter net loss decreases to $1,899,000

Screening colonoscopy rates for women do not increase when offered to be done by female endoscopists: Study

SU2C to receive second CLIO Healthcare Award

Alnylam Pharmaceuticals presents ALN-VSP Phase I data for liver cancer at Chemotherapy Foundation Symposium

Exact Sciences completes underwritten public offering

Data from AVEO's tivozanib-FOLFOX6 combination Phase 1b trial presented at 22nd EORTC-NCI-AACR

Neogenix awarded $488,958.50 grant under QTDP program

Study demonstrates potent anticancer properties of quinoxalinyl-piperazine compounds

Genetic region linked to survival in patients with advanced bowel cancer

Statins do not reduce risk for colorectal cancer in postmenopausal women

Study finds anti-gout medication may reduce risk of colorectal cancer

Laparoscopic surgery safe and effective for removing bowel tumours

New findings could help scientists devise optimal therapies for Friedreich's ataxia

Plexxikon's PLX4032 shows positive data in patients with metastatic melanoma

Exact Sciences awarded $244,500 federal grant to develop Cologuard sDNA screening test

Immunomedics product candidates, technologies receive recognition from QTDP program

Mouse study indicates black raspberries can prevent colorectal cancer

Pro-Pharmaceuticals awarded $489,000 in federal grants under Qualifying Therapeutic Discovery Project

NSAIDs drugs prevent colon cancer: Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in